The radiotherapeutic PD-L1-i ligands of 225Ac and 177Lu developed in this research, with biokinetic and dosimetric properties suitable for delivering ablative radiation doses at the tumor microenvironment level, could potentially be combined with immune checkpoint inhibitor therapy and enhance the therapeutic effect in various types of cancer. The gene discussed is CD274; the disease is neoplasm.